Selective effects of nitric oxide on the disposition of chlorzoxazone and dextromethorphan in isolated perfused rat livers.
The rapid and direct effects of nitric oxide (NO) donors sodium nitroprusside (SNP) and isosorbide dinitrate (ISDN) on the hepatic and biliary disposition of chlorzoxazone (CZX), a marker of CYP2E1, and dextromethorphan (DEM), a marker of CYP2D1, were studied in a single-pass isolated perfused rat liver model. Livers (n = 30) were perfused with constant concentrations of NO donors (0-120 min) in addition to infusion of CZX or DEM (60-120 min), and periodical outlet and bile samples were collected. Both ISDN and SNP significantly reduced (30 and 60%, respectively) the hepatic extraction ratio of CZX and decreased (50 and 70%, respectively) the recovery of the CYP2E1-mediated metabolite, 6-hydroxychlorzoxazone, in the outlet perfusate and bile. As for DEM, both NO donors increased (up to 3.5-fold) the recovery of the CYP2D1-mediated metabolite dextrorphan (DOR) in the outlet perfusate. However, this was associated with a simultaneous decrease (50-75%) in the excretion of the metabolite into the bile, thus resulting in no change in the overall recovery of DOR as a result of NO donor treatment. The decrease in the biliary excretion of DOR was caused by NO-induced simultaneous reductions in both the conjugation of DOR and biliary clearance of DOR conjugate. Additionally, both SNP and ISDN significantly reduced the metabolism of DEM to 3-hydroxymorphinan, which is mostly regulated by CYP3A2. These studies in an intact liver model confirm the selectivity of the inhibitory effects of NO donors on cytochrome P450 enzymes, which was recently reported in microsomal studies, and expand these inhibitory effects to conjugation pathways.
Vuppugalla
Ragini
R
School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Mehvar
Reza
R
D000429:Alcohol Oxidoreductases / Q000378:metabolism; D000818:Animals; D002753:Chlorzoxazone / Q000031:analogs & derivatives* / Q000378:metabolism; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D000072467:Cytochrome P450 Family 2; D003915:Dextromethorphan / Q000378:metabolism*; D003917:Dextrorphan / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D066298:In Vitro Techniques; D007548:Isosorbide Dinitrate / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D009599:Nitroprusside / Q000494:pharmacology; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D014468:Umbelliferones / Q000378:metabolism
D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004791:Enzyme Inhibitors; D020030:Nitric Oxide Donors; D014468:Umbelliferones; D003917:Dextrorphan; D009599:Nitroprusside; C039289:6-hydroxychlorzoxazone; C031477:7-hydroxycoumarin; C039928:7-hydroxycoumarin glucuronide; D003915:Dextromethorphan; D000429:Alcohol Oxidoreductases; D019392:Cytochrome P-450 CYP2E1; C504568:Cyp2d1 protein, rat; D000072467:Cytochrome P450 Family 2; D014453:Glucuronosyltransferase; D002753:Chlorzoxazone; D007548:Isosorbide Dinitrate